Royal Canin taps Jennifer Cullen to lead U.S. vet business

Royal Canin North America has named Jennifer Cullen as general manager of its U.S. Veterinary Business Unit, in a move that places a consumer health executive atop one of the industry’s most important therapeutic nutrition businesses. The company announced the appointment on July 9, 2026, and said Cullen’s role is effective June 2026. She will also join the Royal Canin North America leadership team. (prnewswire.com)

Cullen arrives as Royal Canin is reshaping parts of its North American leadership bench. In February, the company promoted Kira Best to general manager of Healthy Pet & Pet Specialty, and in July parent company Mars named Christina Ruggiero as regional president of Mars Pet Nutrition North America. That broader leadership activity suggests Mars and Royal Canin are aligning commercial and brand leadership at a time when pet nutrition companies are competing more aggressively on innovation, channel strategy, and veterinary engagement. (prnewswire.com)

According to Royal Canin, Cullen most recently served as head of commercial operations for North America at Kenvue. The company said her background spans sales, marketing, brand building, and healthcare leadership across Kenvue and Johnson & Johnson, including prior service as vice president of the Self Care division. In announcing the move, Royal Canin regional president Daryn Brown said Cullen’s experience would support the company’s therapeutic nutrition portfolio and help expand access to nutrition for pets with specialized needs. (prnewswire.com)

The timing matters. Royal Canin’s veterinary business has been especially active in 2026. At VMX in January, the company previewed GLYCOADVANCED, a feline diet for overweight diabetic cats, as well as home care kits tied to dermatology, gastrointestinal, and urinary conditions. It also signaled that veterinary fresh nutrition was coming later in the year. On July 14, Royal Canin formally launched its first fresh therapeutic diet portfolio in the U.S., available exclusively through veterinarians, adding a new format to its existing wet and dry therapeutic lines. (prnewswire.com)

This also follows a prior leadership transition in the same business unit. In July 2024, Heather Pasquale was named general manager of the U.S. Vet Business Unit, charged with growing the veterinary business through stronger customer relationships, broader product offerings, and education for veterinary partners. Cullen’s appointment indicates another handoff in less than two years, though Royal Canin’s announcement did not explain Pasquale’s next role or the reason for the change. That leaves some open questions about continuity, but it also underscores how strategically important the U.S. veterinary channel remains inside Royal Canin. (prnewswire.com)

Direct outside commentary on Cullen’s appointment was limited at publication time, but the company’s own framing is revealing. Royal Canin emphasized her ability to build engaged teams and strengthen brands, while Brown pointed specifically to veterinary partners and expanding access to therapeutic nutrition. That language points to a commercially minded brief: not just product stewardship, but execution across clinic relationships, education, and adoption. This is an inference based on the company’s wording and the timing of recent launches. (prnewswire.com)

Why it matters: For veterinary professionals, leadership changes at Royal Canin are worth tracking because the company has outsized influence on therapeutic diet availability, clinic nutrition workflows, and pet parent adherence. A leader coming from large-scale human health and consumer operations may bring sharper focus to commercialization, omnichannel support, and practice-facing tools. If that happens, clinics could see more resources tied to fresh therapeutic diets, subscription or continuity programs, and educational materials aimed at improving compliance for long-term nutrition plans. Those implications are partly inferential, but they fit Royal Canin’s recent emphasis on home care kits, subscription bridges, and expanded therapeutic formats. (prnewswire.com)

What to watch: The next signals will likely be whether Royal Canin pairs this leadership move with additional veterinary product launches, channel programs, or practice support initiatives in the second half of 2026, especially around fresh therapeutic nutrition and other specialty diets already previewed this year. (prnewswire.com)